15 research outputs found
Recommended from our members
Plasma production and confinement in the Baseball II mirror experiment
Recommended from our members
Directions for possible upgrades of the Mirror Fusion Test Facility (MFTF)
The Mirror Fusion Test Facility (MFTF) may be upgraded by extending the time of plasma sustenance in an approach to steady-state operation and/or by increasing the neutral-beam injection energy. Some parameter bounds for these upgrades are discussed as they relate to a definition of the required neutral-beam development
Recommended from our members
A high-fluence fusion neutron source
A conceptual design of a D-T fusion facility for continuous production of 14-MeV neutron wall loading from 5 to 10 MW/m/sup 2/ at the plasma surface is presented. In this design, D-T neutrons are produced in a linear, two-component plasma formed by neutral beam irradiation of a fully ionized warm plasma target. The beam energy, which is deposited in the center, is transferred to the warm plasma mainly by electron drag and is conducted along the target plasma column to end regions where it is absorbed in neutral gas at high pressure. The target plasma is operated in a regime where electron thermal conduction along the column is the controlling energy-loss process. The loss rate is minimized by adjusting the diameter and length of the plasma column. A substantial gradient in T/sub e/ along the column results in recombination of the plasma to gas in the end-regions before impact on the end walls. The resultant hot gas is cooled by contact with large-area heat exchangers. In this way, the large steady-state heat load from the injected neutral beams is diffused and removed at tolerable heat flux levels. The reacting plasma is essentially an extrapolation of the 2XIIB high-..beta.. plasma to higher magnetic field, ion energy, and density. 12 refs., 4 figs
Rôle of Domain Engineering in Software Development—Why Current Requirements Engineering Is Flawed !
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hotspot region including a screening (n=1283) and two validation cohorts (UK CLL4 trial patients, n=366; CLL Research Consortium (CRC) patients, n=490). Targeted deep-sequencing of 27 known/postulated CLL driver genes was also performed in 38 EGR2-mutated patients to assess concurrent mutations. EGR2 mutations were detected in 91/2403 (3.8%) investigated cases, and associated with younger age at diagnosis, advanced clinical stage, high CD38 expression and unmutated IGHV genes. EGR2-mutated patients frequently carried ATM lesions (42%), TP53 aberrations (18%) and NOTCH1/FBXW7 mutations (16%). EGR2 mutations independently predicted shorter time-to-first-treatment (TTFT) and overall survival (OS) in the screening cohort; they were confirmed associated with reduced TTFT and OS in the CRC cohort and independently predicted short OS from randomization in the UK CLL4 cohort. A particularly dismal outcome was observed among EGR2-mutated patients who also carried TP53 aberrations. In summary, EGR2 mutations were independently associated with an unfavorable prognosis, comparable to CLL patients carrying TP53 aberrations, suggesting that EGR2-mutated patients represent a new patient subgroup with very poor outcome. © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved